Search results
Results from the WOW.Com Content Network
288.50 Leukocytopenia, unspecified; 288.51 Lymphocytopenia; 288.6 Elevated white blood cell count. 288.60 Leukocytosis, unspecified; 288.61 Lymphocytosis (symptomatic) 288.62 Leukemoid reaction; 288.63 Monocytosis (symptomatic) 288.64 Plasmacytosis; 288.65 Basophilia; 288.66 Bandemia; 288.8 Other specified disease of white blood cells; 288.9 ...
Essential thrombocythemia is sometimes described as a slowly progressive disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic events. [15] However, well-documented medical regimens can reduce and control the number of platelets, which reduces the risk of these thrombotic or hemorrhagic events.
However, in essential thrombocythemia where platelet counts are over 750x10 9 /L or 1,000x10 9 /L, especially if there are other risk factors for thrombosis, treatment may be needed. Selective use of aspirin at low doses is thought to be protective.
Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. [ 1 ] It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion .
Thrombocytosis: Idiopathic thrombocytopenic purpura: D69.3: 6673: D016553 Idiopathic thrombocytopenic purpura (ITP) is the condition of having a low platelet count (thrombocytopenia) of no known cause . Recurrent thrombosis: Hemophilia: Hemophilia A: Hemophilia B: Hemophilia C: Von Willebrand disease: Antiphospholipid syndrome: Thrombocytopenia
Von Willebrand factor (VWF) (German: [fɔn ˈvɪləbʁant]) is a blood glycoprotein that promotes hemostasis, specifically, platelet adhesion. It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura , Heyde's syndrome , and possibly hemolytic–uremic ...
Thrombocytosis (increase in the number of platelets) Myeloproliferative disorder; Transient myeloproliferative disease; Coagulopathies (disorders of bleeding and coagulation) Thrombocytosis; Recurrent thrombosis; Disseminated intravascular coagulation; Disorders of clotting proteins Hemophilia. Hemophilia A; Hemophilia B (also known as ...
A third Imago-sponsored global clinical trial for the treatment of essential thrombocythemia was begun in 2020. [10] The results of this global study have also been presented at the American Society of Hematology and the European Hematology Association. A fourth trial begun in 2023 for the treatment of polycythemia vera is ongoing. [11]